Regulatory Context The FDA issued a notice in 2023 removing BPC-157 from the list of bulk substances that may be compounded under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act [2]
Note: Compounded medications are prepared based on specific patient needs and are not reviewed or approved by the FDA for safety or effectiveness
Consider them for improved vitality for lasting benefit
After occlusion of the inferior caval vein, accordingly, BPC 157 counteracts the whole Virchow triad (Vukojevic et al., 2018) and inferior caval vein syndrome (Vukojevic et al., 2018)
Peptide therapy has quickly gained popularity in Manhattan as more people seek advanced treatments to improve energy, slow aging, enhance recovery, and support overall wellness